Eli Lilly stock falls 0.61 percent as pipeline data arrive

Published on 10/04/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly stock traded at USD 1,142.85 after October 2, 11.59 percent below its 52-week high. Q2 revenue reached USD 22.97 billion, up 47.7 percent year over year.

Bauhaus-Grafikposter mit abstrakten geometrischen Formen in Rot, Blau, Gelb und Schwarz, symbolisiert Halbleiter-Fertigung — Lam Research US5324571083 Bauhaus Poster abstrahierter Halbleiter Prozess in geometrischen Primärfarben Rot Blau Gelb, Illustration mit AI erstellt.

Eli Lilly and Co. (ISIN US5324571083) closed at USD 1,142.85 on the NYSE on October 2, 2026, down 0.61 percent for the session. The latest pipeline updates keep the focus on Lilly's obesity, diabetes and oncology franchises as the company approaches its October earnings date.

Pipeline data deepen the story

On October 2, Stock Analysis reported that Lilly announced an expanded FDA indication for Jaypirca, widening the commercial reach of its oncology portfolio. The announcement followed new Foundayo data published by Eli Lilly and Company on October 1, including post-hoc analyses associated with lower predicted long-term risks of type 2 diabetes and cardiovascular disease.

For the market, the combination matters because it adds pipeline evidence beyond Mounjaro and Zepbound. The stock still finished 11.59 percent below its 52-week high of USD 1,292.65, leaving the valuation debate tied to whether new products can extend the company's growth cycle.

Q2 revenue rose 47.7 percent

In Q2 2026, Eli Lilly reported revenue of USD 22.97 billion, up 47.7 percent from the prior year, and EPS of USD 8.38 versus a USD 6.40 consensus estimate, according to MarketBeat in its August 5, 2026 results summary. The revenue increase and earnings comparison provide the clearest operating benchmark ahead of the next report.

Consensus target stays above price

MarketBeat lists a Moderate Buy consensus from 30 analysts, with 25 Buy, 3 Hold, 1 Sell and 1 Strong Buy ratings. The average twelve-month target is USD 1,311.96, with a USD 900.00 low and USD 1,600.00 high; the average target lies 14.80 percent above the October 2 closing price.

The next scheduled checkpoint is October 29, 2026, when Lilly is set to report Q3 2026 results, according to Zacks. That report will test whether the Q2 growth rate is carrying into the second half.

Stock remains below its yearly high

Eli Lilly stock closed at USD 1,142.85 on the NYSE on October 2, 2026, with a market capitalization of USD 1.1 trillion and volume of 2,020,098 shares.